About Adherium

Adherium Limited is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers.

Adherium’s Hailie® sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and COPD, and reduce direct and indirect healthcare costs. Together with our strategic partners, we are developing new generation technology and working to deliver value to payers and providers, while maximizing the positive reimbursement environment with remote patient monitoring (RPM) payments now in place.

Our Vision

To be the leading digital solution for the management of respiratory disease; integrating devices and data to optimise outcomes for patients, healthcare professionals and payers.

Our Values

  • Integrity – we are an ethical company that operates with honesty, trust and respect, and conducts our business with the highest of professional standards.
  • Innovation – we are passionate about technology and push the boundaries to continually develop and evolve smart solutions that deliver value to physicians and payers and improve patients' lives.
  • Accountability - we are a reliable partner and we hold ourselves accountable for our actions and deliver on all our commitments.
  • High Performance – we are reliable, collaborative and committed to the highest of standards, keeping quality at the centre of everything we do.
  • Customer-Focused – we listen to our customers and continually work to deliver quality products and services, consistently delivering solutions that meet and exceed expectations.

Our People

Meet The Executive Management Team

Adherium has a highly experienced executive team capable of leading the development and execution of our strategic plan.

Senior Management

Adherium has a committed, multi-disciplinary management team, focused on achieving our objective of being the international leader in digital solutions for the management of respiratory disease.

Meet The Board of Directors

The Adherium board of directors bring together individuals with multidisciplinary and complementary skill sets which support Adherium’s current and future objectives.

Our Strategic Partners

Our strategy involves working with leaders in respiratory therapy and technology innovation as we develop next generation technology, and focus commercial efforts in the US.

Planet Innovation

Planet Innovation

Innovation

Adherium is working with Melbourne-based Planet Innovation to develop software and hardware with physiological data capture that will enable US physicians to be reimbursed for remotely managing their patients via the Hailie®️ app. This development will further enhance Adherium’s leading device coverage position in both asthma and COPD.

Funding of $5 million for these innovations was secured from the Bioscience Managers Translation Fund 1 in 2020.

The physiological data capture upgrade to Hailie® sensors is expected to be available in 2021.

HGE Health

HGE Health

Disease Management

HGE Health is a full-service RPM solution provider in the chronic obstructive pulmonary disease (COPD) space with plans to expand into asthma RPM. Their payer risk-share contracts deliver immediate recurring revenue streams that will increase with access to new current procedural terminology (CPT) codes.

The collaboration will focus initially on the COPD patient group with an immediate target of those particularly at risk from COVID-19. HGE Care is contracted by payers and providers primarily in New Jersey, Pennsylvania, Oklahoma, and Arizona, for the management of COPD patients, with near term expansion planned into Florida, Texas, Illinois, New Mexico and Montana. Following this initial evaluation Adherium and HGE Health expect to expand the offering to new and existing customers for remote asthma management. 

Monaghan

Monaghan

US Distribution

Monaghan’s dedicated commercial teams sell innovative, market-leading respiratory drug delivery devices and management solutions across the USA. With Monaghan adding Hailie® technology to their specialist offering, this will complement and expand their portfolio.

Given the rapid development of telehealth, with adoption further accelerated through the COVID-19 pandemic, both companies believe that adding Adherium’s inhaler sensor reporting monitoring capability to the Monaghan portfolio is highly commercially attractive and will improve medication adherence in patients with the highest unmet need and resource utilisation, enhancing outcomes and reducing costs to healthcare systems.

We are excited to bring this technology to our customers and provide them with a platform to help guide treatment decisions based on real-life data. Monaghan is dedicated to improving the lives of people with respiratory conditions, and our partnership with Adherium will allow us to advance that goal. Our strong customer relationships provide Adherium with a unique opportunity to bring the Hailie® platform to targeted facilities across the US. It will complement our current product offering and provide us with the opportunity to expand into the digital space, while offering clinicians new ways to manage their patients remotely.

Bill Seitz, Vice President of Sales & Marketing, Monaghan Medical Corporation

Planet Innovation is pleased to be collaborating with Adherium to support their innovation investment in Melbourne as it upgrades its existing software and devices and develops the next set of products with enhanced physiological measurement capabilities.”

Sam Lanyon, Co-CEO and co-founder Planet Innovation

Knowing whether patients are in compliance with their prescriptions will allow the effectiveness of different medications to be evaluated on a patient by patient basis. [The] ability to monitor and consider medication adherence is appealing to our existing customers and partners.

Michael J. Markus, CEO HGE Health

“There is a real synergy between the Hailie® platform and the Monaghan portfolio... This as a real opportunity especially for uncontrolled, paediatric and adult patients, initially focused in asthma, where there is a high burden of disease and consumption of healthcare time and costs in secondary/tertiary care.”

Gerald Slemko, CEO Trudell Medical Limited and President of Monaghan Medical Corporation